MedPath

a study on siddha trail drug KUTTATHIRKU CHOORANAM (INT) & VEPPAMPATTAI THYLAM (EXT) & PRANAYAAMAM (THERAPY) in patients having psoriasis

Phase 2
Not yet recruiting
Conditions
THEATHRU KUTTAM (PSORIASIS)
Registration Number
CTRI/2018/05/013644
Lead Sponsor
government siddha medical college
Brief Summary

This is an open clinical study to evaluate the efficacy of KUTTATHIRKUCHOORANAM (INT) VEPPAMPATTAI THYLAM (EXT) .8oomg of KUTTATHIRKU CHOORANAM and sufficient quantity of VEPPAMPATTAI THYLAM will be given for 48 days. PRANAYAAMAM (THERAPY) is given for all the patients.sample size is 40.the trail drugs KUTTATHIRKU CHOORANAM (INT) VEPPAMPATTAI THYLAM (EXT) contains  some herbs and metals  having anti-oxidant,immune modulator  properties which will be helpful to manage psoriasis

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Patches with Scaling Auspitz Sign positive Koebner’s Phenomenon positive.

Exclusion Criteria

Psoriasis with secondary infection in the lesions Alcoholism & Narcotic addicts History of long term intake of Steroids Cardiac disease Renal failure Pregnancy women and Lactating women Peptic ulcer Psoriatic Orthopedica.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
outcome is mainly assessed by reduction in clinical symptoms like itching and scaling.PASI Score (Psoriasis area severity index)12 Months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

arignar anna hospital of indian medicine

🇮🇳

Chennai, TAMIL NADU, India

arignar anna hospital of indian medicine
🇮🇳Chennai, TAMIL NADU, India
Dr K Thirugnanam
Principal investigator
8122462463
rk.thiru73@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.